Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study

Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry

(2010) B. Glintborg et al.   ANNALS OF THE RHEUMATIC DISEASES

Predicting response to anti-TNF treatment in rheumatoid arthritis patients

(2009) Fabiola Atzeni et al.   AUTOIMMUNITY REVIEWS

Effectiveness, Safety, and Predictors of Good Clinical Response in 1250 Patients Treated with Adalimumab for Active Ankylosing Spondylitis

(2009) M. RUDWALEIT et al.   JOURNAL OF RHEUMATOLOGY

Etanercept in the Longterm Treatment of Patients With Ankylosing Spondylitis

(2009) B. DIJKMANS et al.   JOURNAL OF RHEUMATOLOGY

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial

(2008) D van der Heijde et al.   ANNALS OF THE RHEUMATIC DISEASES

Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis

(2008) M K de Vries et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period

(2008) Jürgen Braun et al.   ARTHRITIS AND RHEUMATISM

The comparative one-year performance of anti–tumor necrosis factor α drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Results from a longitudinal, observational, multicenter study

(2008) Marte Schrumpf Heiberg et al.   ARTHRITIS AND RHEUMATISM